NRT6008 / Chengdu New Radiomedicine Technology - LARVOL DELTA

Safety and Efficacy of NRT6008 Administered in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Carcinoma (LAPC) (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: NRT MedTech Australia Pty Ltd

New P1 trial • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Safety and Efficacy of NRT6008 in Patients with Unresectable Locally Advanced Pancreatic Cancer (LAPC) (clinicaltrials.gov) - P1 | N=58 | Recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2026 ➔ Jun 2028 | Trial primary completion date: Dec 2026 ➔ Dec 2027

Enrollment open • Trial completion date • Trial primary completion date • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) (clinicaltrials.gov) - P1 | N=58 | Not yet recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Initiation date: Mar 2024 ➔ Sep 2024

Metastases • Trial initiation date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) (clinicaltrials.gov) - P1 | N=58 | Not yet recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD.

Metastases • New P1 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor